Abstract
Gamma-irradiation of blood products is mandatory to avoid graft versus host disease in patients with immunosuppressed clinical conditions. Pathogen inactivation techniques were implemented to optimize safe blood component supply. The INTERCEPT treatment uses amotosalen together with UVA irradiation. The functional and molecular implications of these essential treatments have not yet been systematically assessed. The irradiation-induced inactivation of nucleic acids may actually be accompanied with modifications of chemically reactive polyunsaturated fatty acids, known to be important mediators of platelet functions. Thus, here we investigated eicosanoids and related fatty acids released upon treatment and during platelet storage for 7 days, complemented by the analysis of functional and metabolic consequences of these treatments. In contrast to gamma-irradiation, here we demonstrate that UVA treatment attenuated the formation of ALOX12-products such as 12-HETE and 12-HEPE but induced the formation of trans-arachidonic acids in addition to 11-HETE and HpODEs. Metabolic and functional issues like glucose consumption, lactate formation, platelet aggregation and clot firmness hardly differed between the two treatment groups. In vitro synthesis of trans-arachidonic acids (trans-AA) out of arachidonic acid in the presence of β-mercaptoethanol suggested that thiol radicals formed by UVA treatment are responsible for the INTERCEPT-specific effects observed in platelet concentrates. It is plausible to assume that trans-AA and other UVA-induced molecules may have specific biological effects on the recipients, which need to be addressed in future studies.
Key points
A previously unrecognized radical mechanisms for the generation of trans-fatty acids by UVA was identified
Irradiation with UVA was found to immediately affect the generation of polyunsaturated fatty acid oxidation products
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Ethics Committee of the Medical University of Vienna. All donors gave written informed consent to participate in this study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
Abbreviations
- AA
- arachidonic acid
- CAD
- compound adsorption device
- CFT
- clot formation time
- EtOH
- ethanol
- FA
- formic acid
- HETEs
- hydroxyeicosatetraenoic acids
- HPLC
- high-performance liquid chromatography
- HpODEs
- hydroperoxyoctadecadienoic acids
- LDH
- lactatdehydrogenase
- LTA
- light transmission aggregometry
- MA
- maximal aggregation
- MCF
- maximal clot firmness
- MeOH
- methanol
- MS
- mass spectrometry
- PCs
- platelet concentrates
- PI
- pathogen inactivation
- Plt
- platelet
- PR
- pathogen reduction
- rWBC
- residual white blood cells
- SD
- standard deviation
- SPE
- solid-phase extraction
- TA-GvHD
- transfusion associated graft versus host disease
- TEM
- thromboelastometry
- TRAP-6
- thrombin receptor agonist peptide-6
- TTIs
- transfusion transmitted infections
- yIRR
- gamma irradiation